Literature DB >> 31290849

Assessing EGFR gene mutation status in non-small cell lung cancer with imaging features from PET/CT.

Mengmeng Jiang1, Yiqian Zhang2, Junshen Xu3, Min Ji2, Yinglong Guo4, Yixian Guo1, Jie Xiao5, Xiuzhong Yao4, Hongcheng Shi5, Mengsu Zeng6.   

Abstract

OBJECTIVE: The aim of this study was to investigate whether quantitative and qualitative features extracted from PET/computed tomography (CT) can be used as imaging biomarkers for evaluating epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer patients.
METHODS: Eighty patients with stage II and III non-small cell lung cancer from January 2017 to December 2017 were included in this study. All patients underwent PET/CT examination before operation. Patients with 30 EGFR positive and 50 EGFR negative were confirmed by pathological verification and gene detection. Least absolute shrinkage and selection operator was used for analysis and selection of imaging features. Support vector machine was used to classify EGFR positive/negative using the selected features. Ten-fold cross validation was used to estimate the accuracy.
RESULTS: A total of 512 quantitative features (radiomic features) were extracted from PET/CT (256 for PET and 256 for CT), and 12 qualitative features (semantic features) were extracted from CT. A total of 35 features were finally retained after least absolute shrinkage and selection operator (31 quantitative features and 4 qualitative features). The 35 selected features were significantly associated with EGFR mutation status. A predictive model was built using PET/CT data. Its performance was revealed as 0.953 using the area under the receiver operating characteristic curve.
CONCLUSION: A predictive model using PET/CT images might be used to detect EGFR mutation status in non-small cell lung cancer patients.

Entities:  

Year:  2019        PMID: 31290849     DOI: 10.1097/MNM.0000000000001043

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  8 in total

Review 1.  Radiogenomics Based on PET Imaging.

Authors:  Yong-Jin Park; Mu Heon Shin; Seung Hwan Moon
Journal:  Nucl Med Mol Imaging       Date:  2020-05-09

Review 2.  Radiomics in Oncological PET Imaging: A Systematic Review-Part 1, Supradiaphragmatic Cancers.

Authors:  David Morland; Elizabeth Katherine Anna Triumbari; Luca Boldrini; Roberto Gatta; Daniele Pizzuto; Salvatore Annunziata
Journal:  Diagnostics (Basel)       Date:  2022-05-27

3.  Prediction of EGFR Mutation Status in Non-Small Cell Lung Cancer Based on Ensemble Learning.

Authors:  Youdan Feng; Fan Song; Peng Zhang; Guangda Fan; Tianyi Zhang; Xiangyu Zhao; Chenbin Ma; Yangyang Sun; Xiao Song; Huangsheng Pu; Fei Liu; Guanglei Zhang
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

Review 4.  Progress and future prospective of FDG-PET/CT imaging combined with optimized procedures in lung cancer: toward precision medicine.

Authors:  Haoyue Guo; Kandi Xu; Guangxin Duan; Ling Wen; Yayi He
Journal:  Ann Nucl Med       Date:  2021-11-02       Impact factor: 2.668

Review 5.  The application of radiomics in predicting gene mutations in cancer.

Authors:  Yana Qi; Tingting Zhao; Mingyong Han
Journal:  Eur Radiol       Date:  2022-01-20       Impact factor: 5.315

6.  The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.

Authors:  Virginia Liberini; Riccardo Laudicella; Martina Capozza; Martin W Huellner; Irene A Burger; Sergio Baldari; Enzo Terreno; Désirée Deandreis
Journal:  Molecules       Date:  2021-04-11       Impact factor: 4.411

Review 7.  Artificial intelligence and hybrid imaging: the best match for personalized medicine in oncology.

Authors:  Martina Sollini; Francesco Bartoli; Andrea Marciano; Roberta Zanca; Riemer H J A Slart; Paola A Erba
Journal:  Eur J Hybrid Imaging       Date:  2020-12-09

8.  3D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma.

Authors:  Guixue Liu; Zhihan Xu; Yingqian Ge; Beibei Jiang; Harry Groen; Rozemarijn Vliegenthart; Xueqian Xie
Journal:  Transl Lung Cancer Res       Date:  2020-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.